Current Status
Not Enrolled
Price
¤$149
Get Started

Course

California Schedule II Controlled Substances and Neonatal Abstinence Syndrome

Contact Hours Awarded: 2 , including 2 pharmacology contact hours

Start Course
Now

Course Overview

California Schedule II Controlled Substances and Neonatal Abstinence Syndrome

Author: Edith Fomuso

MSN, RN, CCM, DPM

This course is designed for Certified Nurse Midwives in California who wish to furnish Schedule II Controlled Substances. Assembly Bill 1196, Chapter 478 requires completing a Board-approved two contact hour educational activity before application. The pharmacokinetic and pharmacodynamic principles regarding Schedule II drugs and the risks of neonatal abstinence syndrome will be discussed, as well as the ethical and legal requirements associated with their use. 

Course Outline

  1. Introduction
  2. Schedule II Controlled Substances and Women’s Health
    Overview of Schedule II Controlled Substances
    Significance of Using Schedule II Controlled Substances in Pharmacotherapeutic Management of Women’s Health
  3. Rationale for Using Schedule II Controlled Substances Outside Acute Care Hospitals.
  4. Pharmacokinetics and Pharmacodynamics of Schedule II Controlled Substances
    Pharmacokinetics
    – Pharmacodynamics
  5. Application of Pharmacokinetic and Pharmacodynamic Principles to Women’s Health Conditions.
  6. Addiction and Neonatal Abstinence Syndrome
    Understanding Addiction
    Understanding Neonatal Abstinence Syndrome (NAS)
    Preventive Strategies for Addiction and Neonatal Abstinence Syndrome
    Holistic Approach to Addressing Addiction and Neonatal Abstinence Syndrome (NAS)
  7. Legal Framework for Dispensing Controlled Substances
  8. Federal and State Regulations on Controlled Substances.
  9. Dispensing Vs. Administering: Understanding the Difference
  10. Nurse-midwife’s Role in Ensuring Compliance with Legal Requirements
  11. Patient-Specific Protocols
    Importance of Patient-specific Protocols in Schedule II Controlled Substance Use
    Components of Patient-Specific Protocols
    Aligning Protocols with the Business and Profession Code, Section 2746.51
  12. Conclusion

Accreditation Statement

Nursing CE Central LLC is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

In this course, we will discuss Schedule II controlled substances and safe prescribing considerations for Certified Nurse Midwives in the State of California. It will take the average learner 120 minutes to complete and awards 2 contact hours of continuing education, including 2 pharmacological contact hours.

Course Outcomes

After completing this course, the learner will rate a 4 out of 5 on the Likert Scale for their ability to:

  1. Demonstrate an understanding of the pharmacokinetics and pharmacodynamics related to Schedule II controlled substances in relationship to women’s health and neonatal care. 
  2. Analyze state laws and federal regulations about furnishing, dispensing, and administering Schedule II controlled substances for out-of-hospital patient use. 
  3. Outline the required components of a furnishing standardized procedure or protocol for Schedule II controlled substances. 

Target Audience

  • Registered Nurses (RN)
  • Advanced Practice Registered Nurses (APRN)
  • Licensed Practical Nurses (LPN/LVN)

Requirement for Completion

  1. Enrollment in the course by the learner
  2. Read and learn all course materials
  3. Complete the course evaluation
  4. Attest and testify learning of the course materials

Accreditations + Approvals

  • American Nurses Credentialing Center (ANCC) (P0614)
  • California Board of Registered Nursing (CEP 17418)
  • Kentucky Board of Nursing (7-0090)
  • Louisiana State Board of Nursing (58)
  • New York State Department of Education (IC 208)
  • Florida Board of Nursing (50-23983)

Disclosure of Relevant Financial Relationships

Nursing CE Central nor any of the authors, planners, content experts, or any contributors have any relevant financial relationships with ineligible companies to disclose.

Start Course
Now

Course created on: September 01, 2023

Course Expires on: September 01, 2026

Course Offering: #182